Danish biotechnology company Zealand Pharma A/S (NASDAQ:ZEAL) (CPH:ZEAL) has completed patient enrolment in its pivotal Phase 3 trial (EASE-SBS 1) of glepaglutide, the company announced on Thursday.
Glepaglutide, Zealand Pharma's long-acting GLP-2 analog, is a potential new treatment for short bowel syndrome (SBS). It is being investigated for once or twice weekly administration with an autoinjector and has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA).
Full results of the trial are expected in the third quarter of 2022.
With completion of patient enrolment into EASE-SBS 1, the EASE-SBS 2 extension trial has been amended to allow for direct enrolment without prior participation in EASE-SBS 1. The EASE-SBS 2 trial is a two-year Phase 3b trial assessing safety and efficacy of glepaglutide dosed once and twice weekly.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT